

---

# Index

## A

Absorption, distribution, metabolism, excretion (ADME), 116, 124–126  
Acute lymphoblastic leukaemia (ALL), 58, 73, 74  
Acute myocardial infarction (AMI), 347, 352–356  
Affinity chromatography, 63  
Aging, 259, 265, 266  
Alexion Pharmaceuticals Inc., 211, 212, 214–217, 219, 220, 226, 227  
Alkaline phosphatase (ALP), 202–204, 207, 210, 224, 227  
Amino acid addictions, 175–177, 192  
Amyloid beta (A $\beta$ ), 98  
Analytical characterization, 141, 143–145  
Animal models, 234, 241  
Anistreplase, 351, 354  
Antibiotics, 234, 235, 238–240, 242, 244, 246, 248, 249  
Antibody–drug conjugates (ADCs), 76  
Anticoagulants, 347–351, 357, 360, 362, 363, 365  
Anti–drug antibodies (ADAs), 68  
Antiplatelet drugs, 350, 351  
Arginine deiminase (ADI), 94–95  
Asfotase alfa, 74–76, 202, 208, 210–228  
    adverse effects, 310, 311  
    in clinical trials and case reports, 280, 298, 303, 305–311, 314  
    dosage and administration, 310, 311  
    preclinical studies, 296, 298  
    treatment effects on hypophosphatasia, 306  
Asparaginases (ASNases), 93, 94

## B

Bacteriophages, 234, 235  
Bioavailability, 118, 119  
Bioburden, 69  
Bone, 202–211, 213, 217, 220–222, 224–228

## C

Cancer, 174–193  
Cancer addictions, 175, 191  
Capillary isoelectric focussing (cIEF), 66, 67  
Catabolism, 120, 121

CD44, 258

Cell lysis, 60, 61, 73  
Characterisation of enzymes, 65  
CHO cell line, 28, 50  
Chronic pancreatitis, 334–339  
Clinical trials, 234, 244, 245, 250  
Coatings, 165, 166  
Column chromatography, 61, 73  
Cross-linking, 138, 140, 142  
Crude enzyme preparation, 73

## D

Dental, 203–205, 208, 221  
Design of experiments (DOE), 69  
Desmoteplase, 351, 355–357  
Diffusion, 259, 260, 262  
Dimerization, 117–120, 124  
Disposable technology, 59  
Downstream processing (DSP), 59–61, 63, 64, 68, 70, 72–77  
Drug resistance, 175  
Drug substance (DS), 58–60, 64, 71, 74–76

## E

Efficacy, 124  
Elimination, 119–125  
Endolysins, 234–242, 244–250  
Endotoxins, 69, 70  
Enzybiotics, 234–250  
Enzyme glycosylation, 67, 72, 73, 76  
Enzyme-linked immunosorbent assay (ELISA), 66, 68  
Enzyme replacement therapy (ERT), 133, 134, 137, 139, 141, 202, 208, 210, 211, 221–226  
Enzymes  
    enzyme replacement therapy (ERT), 28, 38–42, 46, 52  
    therapeutic, 28–34, 36–42  
Enzyme stability, 71  
Erwinase<sup>®</sup>, 58, 73–75  
Exogenous enzymes, 154  
Expression of enzymes in plant cells, 72  
Extracellular matrix (ECM), 256, 258–262, 265

Extraction, 60, 61, 73  
 Extraction of enzyme from plant cells, 73  
 Extravasation, 256, 259, 263–265

## F

Fabry disease, 28, 29, 39, 41, 42, 46, 52, 88, 89  
 Fibrinogenolysis, 357, 360–362, 364, 365  
 Fillers, 256, 265–271  
 Fluorescence  
   dye, 107, 109–113  
   history, 107, 113  
   method choosing, 106–108, 110–113  
   polarization, 106–108, 112, 113  
   quenching, 106–108, 111, 112  
   tracing, 106–108, 110  
 Fluorescence resonance energy transfer (FRET),  
   106–108, 110–112  
 Fluorescent protein, 107, 111, 112  
 Fractures, 202, 204–206, 208–210, 221, 225, 227  
 Fusion enzymes, 74–76  
 Future enzyme products, 76

## G

$\alpha$ -Galactosidase A  
   recombinant human  $\alpha$ -galactosidase A, 41–52  
 Gaucher's disease (GD), 57, 58, 72, 87–89  
 Gene expression  
   stable, 30, 33  
   transient, 29, 30  
 Glucocerebrosidase, 69, 72, 73  
 Glycine oxidase (GO), 187, 188  
 Glycosaminoglycan (GAG), 256  
 Glycosylation, 27, 28, 32, 38, 41, 42, 52, 121, 123, 124  
 Good manufacturing practices (GMP), 57, 64, 65, 70  
 Gram-negative bacteria, 238, 247–249  
 Gram-positive bacteria, 234, 237, 238, 241, 244–247, 249  
 GRASPA, 177, 179, 192

## H

Half-life ( $T_{1/2}$ ), 120–124  
 Higher-order structure, 117, 119, 124  
 High-pressure liquid chromatography (HPLC), 65–68,  
   73, 74, 76  
 Host cell proteins (HCP), 67  
 Humanization, 122  
 Hunter syndrome, 90, 91  
 Hurler syndrome, 91, 92  
 Hyaluronan (HA), 256–261, 263, 265–271  
 Hyaluronan synthases (HAS), 256, 258  
 Hyaluronidase (HYAL), 256–271  
 Hydrodynamic radius, 121  
 Hydrophobic interaction chromatography (HIC), 63, 73  
 Hypophosphatasia (HPP), 202–215, 217, 219–228  
   animal models, 292, 293, 295  
   classifications, 285–287, 289  
   diagnosis, 289–292, 307, 308  
   laboratory workup, 290, 291

## I

Identity testing, 65, 66  
 Immobilised-metal affinity chromatography  
   (IMAC), 62, 63  
 Immobilization, 141, 142  
 Immunogenicity, 133, 137, 138, 140, 144, 145  
 Inherited metabolic disorders, 133, 134  
 Inorganic pyrophosphate (PPi), 202, 204, 207, 209, 212,  
   214, 216, 220–222  
 Insulin, 116–119, 124  
 Isoelectric point (pI), 118, 125  
 Isothermal calorimetry, 70

## K

Kidrolase, 178  
 Krabbe disease, 89, 90

## L

L-Asparaginase, 58, 63, 64, 67–69, 73, 74,  
   177–180, 192  
 Lentiviral vectors (LVs), 28, 33–38, 42, 43, 52  
 L-Glutaminase, 185–187  
 Limit of detection (LOD), 68  
 L-methioninase, 176, 183–185  
 Low molecular weight heparins (LMWHs), 349  
 Lumbrokinases (LK), 97, 351, 360  
 Lysosomal acid lipase deficiency (LAL-D), 57, 58  
 Lysosomal storage disease (LSD), 27, 28, 39–41, 52

## M

Mammalian cells, 27, 28, 30, 31, 33  
 Maroteaux–Lamy syndrome, 86  
 Metabolic rewiring, 175  
 Method lifecycle management, 71  
 Microfiltration (MF), 61  
 Miniplasmin, 358  
 Modifications, 135, 138–140, 142, 144, 145  
 Modular enzymes, 238  
 Molecular charge, 118, 119, 122, 123, 125, 126  
 Molecular weight (MW), 116–120, 122, 124, 125  
 Monoclonal antibodies (mAbs), 57, 76, 77,  
   118–122  
 Montepilase, 356  
 Mornet, E., 202, 203, 208, 209  
 Morquio syndrome, 83, 84  
 Mucus, 154, 155, 157, 163, 167  
 Multidrug-resistance, 234, 235, 244,  
   248, 249  
 Mutagenesis, 139, 140, 142, 145  
 Mycobacteria, 237, 238, 249, 250

## N

Native enzyme modification, 165  
 Neonatal Fc receptor (FcRn), 119, 121, 122  
 Nicotine, 98, 99  
 N-terminal sequencing, 64, 66

**O**

Oncaspar, 177, 178, 192  
Oncogenes, 175, 176, 185  
Oncometabolites, 175  
Oncosuppressor genes, 175  
Oral delivery, 153, 155, 165, 167  
Orphan Drug Act, 27, 39, 52

**P**

Pancreatic enzymes, 324–334, 336–339  
Pancreatic insufficiency, 324–339  
Pancreatin, 156, 159, 166, 169  
PEGylation, 120, 121, 159, 160, 165  
Peptide mapping, 65, 66, 74  
Peptidoglycan (PG), 234–241, 247–249  
PH20, 258–260  
Pharmacokinetics (PK), 116, 120, 124, 125  
Phenylketonuria (PKU), 82, 83  
Physical size, 117, 120  
Physiochemical characteristics, 116–118  
Plasminogen activator, 82, 96  
Polymer conjugation, 138, 140, 141, 157, 162, 169  
Polymerase chain reaction (PCR), 66, 68  
Pompe disease, 84–86  
Post-translational modifications, 67  
Potency testing, 68, 69  
Precipitation, 64, 73  
Primary structure, 116, 117, 119, 122–124  
Proline deaminase, 189–191  
Protein A chromatography, 76  
Protein degradation, 138  
Protein engineering, 139, 140  
Protein-polymer engineering, 165, 169  
Protein-protein interaction, 125  
Proteolysis, 138, 140, 141, 145  
Purity testing, 66–68

**Q**

Quality assurance (QA), 57, 58  
Quality by design (QbD), 59, 71  
Quality control (QC), 57, 58, 60, 64–73, 75–77  
Quality management system (QMS), 64

**R**

Recombinant human hyaluronidase (rHuPH20), 259, 260, 262, 263, 271  
Renal filtration, 121, 122  
Replication-competent lentivirus (RCL), 37, 38, 52  
Residual DNA, 68

**S**

Safety testing, 69, 70  
Sanfilippo A syndrome, 84  
Sebelipase alfa, 57  
Seizures, 202, 205, 206, 210, 223, 224, 226

Self-association, 117, 124  
Serine deaminase, 176, 189  
Site-specific mutation, 165, 169  
Size exclusion chromatography (SEC), 65, 66, 68, 74, 76  
Sly syndrome, 92  
Small intestine, 153, 154, 156, 158, 165, 166, 169  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), 66–68, 71, 74, 75  
Spectrila, 178  
Spreading factors, 256, 258, 261, 271  
Standard operating procedures (SOPs), 64  
Staphylokinase (SAK), 351, 355, 357, 358, 364  
Stomach, 153–158, 161, 165, 169  
Strensiq®, 75, 76  
Streptokinase (SK), 351–354, 357, 359, 364, 369  
Structures, 132, 138–140, 143, 144  
Surface plasmon resonance (SPR), 70

**T**

Target-mediated drug disposition (TMDD), 123  
Tenecteplase (TNK), 351, 355, 356  
Therapeutic enzyme market, 57  
Therapeutic enzymes, 132–145  
  applications, 2–5, 10, 19  
  classification, 106  
  development history, 113  
  enzyme engineering, 3, 7  
  large-scale manufacturing  
    downstream process, 9, 10, 17  
    enzyme formulation, 18, 19  
    upstream optimization, 8, 16  
  production of  
    expression platforms  
      bacteria, 13  
      mammalian cells, 9, 17  
      plants, 8, 17  
      yeast, 8, 9, 13, 16  
    purification strategies, 10, 12–15  
    recombinant, 5, 8–10, 12, 13, 16, 17  
  sources, 3, 7  
Therapeutic proteins, 116–126  
Therapeutics, 234–250  
Thrombin inhibitors, 349, 350  
Time to peak concentration (Tmax), 117, 118  
Tissue-non-specific alkaline phosphatase (TNSALP), 202–204, 207–211, 221, 222, 225, 228, 280–285, 290, 292, 293, 295–299, 303–314  
Tooth/teeth, 202, 204–207, 221, 225, 228  
Tumor, 258, 259, 263

Types of column chromatography, 73  
Tyrosine aminotransferase, 191, 192

**U**

U.S. Food and Drug Administration (FDA),  
116, 117, 119, 122, 126  
Ultrafiltration, 64  
Urokinase plasminogen activator (u-PA), 353

**V**

Viral safety of enzymes, 70  
Volume of distribution (Vd),  
118, 119

**W**

Warburg effect, 175  
Whyte, M.P., 202–204, 206, 207, 225